| P2093 | author name string | M Boeckh | |
| P2860 | cites work | Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection | Q33370617 |
| | Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. | Q35816311 |
| | Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. A comparison of seven virologic methods. | Q38484299 |
| | Quantitation of cytomegalovirus: methodologic aspects and clinical applications. | Q39468915 |
| | Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recov | Q39873608 |
| | Cytomegalovirus (CMV)-Specific Intravenous Immunoglobulin for the Prevention of Primary CMV Infection and Disease after Marrow Transplant | Q40745710 |
| | Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes | Q41034377 |
| | Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease | Q43467764 |
| | Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. | Q43473068 |
| | Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses | Q43963645 |
| | Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial | Q44001704 |
| | Treatment of Interstitial Pneumonitis Due to Cytomegalovirus with Ganciclovir and Intravenous Immune Globulin: Experience of European Bone Marrow Transplant Group | Q44229376 |
| | Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes | Q44443155 |
| | Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation | Q44717088 |
| | Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation | Q44799887 |
| | Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group | Q45095772 |
| | Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants | Q45163630 |
| | Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients | Q45767467 |
| | Prevalence of Resistance in Patients Receiving Ganciclovir for Serious Cytomegalovirus Infection | Q46154428 |
| | A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group | Q47573431 |
| | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis | Q50132411 |
| | Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. | Q52307785 |
| | Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients | Q67494224 |
| | Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation | Q68262204 |
| | Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia | Q68469036 |
| | Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation | Q68473570 |
| | Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin | Q69842643 |
| | Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation | Q70135390 |
| | Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial | Q70200006 |
| | Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy | Q70461480 |
| | High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group | Q70705675 |
| | Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients | Q70883328 |
| | Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation | Q71463399 |
| | Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation | Q71735357 |
| | Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation | Q71747101 |
| | Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor | Q72059554 |
| | Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant | Q72940232 |
| | Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial | Q72940234 |
| | Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation | Q72950070 |
| | No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group | Q73063074 |
| | Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Cli | Q73081676 |
| | Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group | Q73261939 |
| | Cytomegalovirus disease occurring before engraftment in marrow transplant recipients | Q73322526 |
| | A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants | Q73322562 |
| | Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation | Q73407683 |
| | Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease | Q73438646 |
| | Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture | Q73536032 |
| | Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group | Q73552614 |
| | Circulating cytomegalovirus (CMV)-infected endothelial cells in marrow transplant patients with CMV disease and CMV infection | Q73683997 |
| | Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infecti | Q74422553 |
| | A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989 | Q74523440 |
| | Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis | Q77065933 |
| | A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation | Q77078751 |
| | Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study | Q77101804 |
| | Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients | Q77292897 |
| | A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation | Q77370754 |
| | Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia | Q77524586 |
| | Reply | Q93923811 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| | stem cell transplantation | Q65592366 |
| P304 | page(s) | 165-178 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Transplant Infectious Disease | Q15749562 |
| P1476 | title | Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy | |
| P478 | volume | 1 | |